• Tidak ada hasil yang ditemukan

Table of Contents of Supplemental Material

N/A
N/A
Protected

Academic year: 2024

Membagikan "Table of Contents of Supplemental Material"

Copied!
6
0
0

Teks penuh

(1)

Table of Contents of Supplemental Material

Supplemental Table 1. Manual annotation of biopsy images

Supplemental Table 2. Coding of soft labels for deep learning training

Supplemental Table 3. Kidney failure risk, calculated by univariable and multivariable Cox Regression analysis of clinical characteristics. Clinical outcome is time to kidney failure.

Supplemental Table 4. Data table of the predictive scores and outcome of the biopsies of the

Final Test set (n = 95 biopsies). Deep Learning Predictive Score (DLPS), MEST-C score, IgAN

Prediction Tool (IIPT), Clinical Decision Support System for Estimating the Risk of End-Stage

Kidney Disease in IgA Nephropathy’(CDSS) and Outcome (kidney failure during the follow up).

(2)

Supplemental Table 1. Manual annotation of biopsy images Feature

Biopsies, n 496

Images, n 1,369

Patches, n 7199

Mean images / biopsy sections, n 3 (2-4)

Compartmentalization by manual annotation

Capsular area per image, µm

2

53,062 (0 – 452,594)

Cortical area per image µm

2

4,734,348 (3,580,022 – 6,807,961)

Medullary area per image µm

2

0 (0 – 3,045,781)

Data are expressed as median (25th – 75th percentile), unless otherwise indicated.

(3)

Supplemental Table 2. Coding of soft labels for deep learning training

Clinical features Label formula Label

Kidney failure during the follow up

Time to kidney failure (TtKF), years

Follow up duration (f-up), years

(range value)

False NA > 5 0 0

False NA ≤ 5 0.5 – (f-up/10) 0.5 – 1

True < 5 NA 1 1

True

5 and <10

NA 0.5 +((10 – TtKF) / 10) 0.5 – 1

True

10

NA 0 0

NA = not applicable, TtKF = time to kidney failure, f-up = follow up

Supplemental Table 3. Kidney failure risk, calculated by univariate and multivariate Cox Regression analysis of clinical characteristics. Clinical outcome is time to kidney failure.

Univariable Analysis

Multivariable Analysis

Parameters Hazard

Ratio

p value Hazard Ratio

p value

Creatinine, mg/dl 2.30 <0.001 2.30 <0.001 Urine Protein/Creatinine ratio 1.80 <0.001 1.59 <0.001 Mean Blood Pressure, mmHg 1.02 <0.001 1.02 <0.001

Age, yrs 1.012 0.05 1.00 0.83

Sex 0.65 0.09 0.91 0.77

Sex coded as male = 1 and female = 2

(4)

Supplemental Table 4. Data table of the predictive scores and outcome of the biopsies of the Final Test set (n = 95 biopsies). Deep Learning Predictive Score (DLPS), MEST-C score, IgAN Prediction Tool (IIPT), Clinical Decision Support System for Estimating the Risk of End-Stage Kidney Disease in IgA Nephropathy’(CDSS) and Outcome (kidney failure during the follow up).

BIOPSY ID

DLPS IIPT DCSS M E S T C OUTCOME

20 0.20 11.19 81.16 0 0 0 1 1 0

21 0.12 6.26 83.60 0 0 0 0 0 0

24 0.27 6.41 83.92 1 1 0 0 0 0

25 0.18 5.51 87.20 0 1 0 0 0 0

52 0.47 5.51 89.92 0 1 0 0 1 0

59 0.28 5.51 89.92 0 1 0 0 1 0

72 0.41 6.06 83.30 0 1 1 0 0 0

73 0.64 11.19 74.79 0 0 0 1 0 0

86 0.56 7.04 78.56 1 1 1 0 0 1

88 0.20 5.51 89.92 0 1 0 0 1 0

89 0.73 12.53 74.44 1 1 1 1 1 1

96 0.38 5.51 89.92 0 1 0 0 1 0

145 0.69 6.06 85.45 0 1 1 0 2 1

156 0.30 6.06 85.45 0 1 1 0 1 0

192 0.15 5.51 87.20 0 1 0 0 0 0

203 0.74 6.06 85.45 0 1 1 0 1 1

213 0.20 5.51 87.20 0 1 0 0 0 0

223 0.17 12.53 66.48 1 1 1 1 0 0

229 0.39 6.41 88.67 1 1 0 0 1 0

235 0.17 6.26 83.60 0 0 0 0 0 0

244 0.36 12.26 64.01 0 0 1 1 0 1

251 0.22 6.26 87.45 0 0 0 0 1 1

256 0.79 12.53 74.44 1 1 1 1 1 1

261 0.14 7.04 83.51 1 1 1 0 1 0

285 0.12 6.06 85.45 0 1 1 0 1 0

313 0.28 6.26 83.60 0 0 0 0 0 0

324 0.79 12.53 74.44 1 1 1 1 1 1

327 0.56 18.56 57.64 0 1 1 2 0 1

328 0.52 6.06 85.45 0 1 1 0 1 0

330 0.19 6.41 83.92 1 1 0 0 0 0

342 0.45 6.06 83.30 0 1 1 0 0 0

348 0.77 10.84 77.91 0 1 1 1 2 1

(5)

385 0.25 6.26 83.60 0 0 0 0 0 0

413 0.79 12.26 72.01 0 0 1 1 1 1

419 0.46 5.51 87.20 0 1 0 0 0 0

426 0.36 9.89 84.46 0 1 0 1 1 0

435 0.37 5.51 87.20 0 1 0 0 0 0

461 0.59 12.26 64.01 0 0 1 1 0 0

862 0.48 20.86 50.58 0 0 1 2 0 0

899 0.91 12.53 66.48 1 1 1 1 0 1

903 0.63 7.27 76.21 1 0 0 0 0 0

910 0.75 23.91 61.50 1 0 1 2 0 0

991 0.32 10.84 72.27 0 1 1 1 0 0

1157 0.56 23.91 54.26 1 0 1 2 1 1

1192 0.54 7.98 77.13 1 0 1 0 1 0

1239 0.34 6.26 83.60 0 0 0 0 0 0

1243 0.48 7.98 77.13 1 0 1 0 1 0

1287 0.17 7.98 67.85 1 0 1 0 0 0

1299 0.24 11.19 74.79 0 0 0 1 0 0

1323 0.56 20.86 50.58 0 0 1 2 0 1

1431 0.59 12.53 74.44 1 1 1 1 1 0

1464 0.40 7.98 77.13 1 0 1 0 1 0

1502 0.16 12.53 74.44 1 1 1 1 1 0

1845 0.32 11.19 74.79 0 0 0 1 0 1

1858 0.07 7.04 83.51 1 1 1 0 1 0

1985 0.16 6.06 83.30 0 1 1 0 0 0

2021 0.31 7.98 67.85 1 0 1 0 0 0

2122 0.12 7.04 78.56 1 1 1 0 0 0

2218 0.38 7.04 83.51 1 1 1 0 1 0

2234 0.26 12.53 74.44 1 1 1 1 1 1

2255 0.13 7.04 78.56 1 1 1 0 0 0

2308 0.77 21.96 54.18 1 0 0 2 0 1

2401 0.21 12.53 74.44 1 1 1 1 1 1

2510 0.12 12.53 74.44 1 1 1 1 1 0

2577 0.03 7.98 67.85 1 0 1 0 0 0

2649 0.19 6.88 80.92 0 0 1 0 1 0

2666 0.63 12.53 74.44 1 1 1 1 1 1

2722 0.38 12.26 64.01 0 0 1 1 0 1

2777 0.52 12.26 64.01 0 0 1 1 0 1

2801 0.09 7.98 67.85 1 0 1 0 0 0

2874 0.12 7.04 83.51 1 1 1 0 1 0

2891 0.37 12.26 64.01 0 0 1 1 0 1

2905 0.53 12.94 65.63 1 0 0 1 0 0

2921 0.16 6.88 77.40 0 0 1 0 0 1

(6)

2972 0.26 6.26 83.60 0 0 0 0 0 0

2975 0.16 10.84 72.27 0 1 1 1 0 0

3011 0.20 7.27 76.21 1 0 0 0 0 0

3018 0.19 7.04 78.56 1 1 1 0 0 0

3032 0.50 7.98 67.85 1 0 1 0 0 0

3180 0.45 NA NA 0 1 NA 0 0 0

3228 0.52 7.98 67.85 1 0 1 0 0 1

3333 0.16 NA NA 0 0 NA 0 0 0

3368 0.28 6.06 85.45 0 1 1 0 1 0

3413 0.47 6.88 77.40 0 0 1 0 0 0

3426 0.81 6.88 80.92 0 0 1 0 1 1

3435 0.41 6.26 83.60 0 0 0 0 0 0

3530 0.16 6.06 83.30 0 1 1 0 0 0

3624 0.50 7.04 78.56 1 1 1 0 0 1

3723 0.51 NA NA NA 0 1 2 1 1

3839 0.75 10.84 77.91 0 1 1 1 1 1

3885 0.67 6.88 77.40 0 0 1 0 0 1

NA = Not Available

Referensi

Dokumen terkait

Promising Biomarkers of Kidney Disease in Urinary EVs Biomarker Origin Isolation method Disease Source EV type Increased pEVs Human Total Exosome Isolation Reagent Invitrogen

Factors associated with cardiovascular mortality after kidney transplantation during childhood and adolescence Supplementary Table 3.. Factors associated with infection-related